{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:34:52Z","timestamp":1793360092109,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07662-9","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T01:03:02Z","timestamp":1765846982000},"page":"3664-3673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-7164","authenticated-orcid":false,"given":"Maaike","family":"Dotinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-2743","authenticated-orcid":false,"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-2119","authenticated-orcid":false,"given":"Floris H.P.","family":"van Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2843-1854","authenticated-orcid":false,"given":"Mette K.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-1009","authenticated-orcid":false,"given":"Jan W.T.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8270","authenticated-orcid":false,"given":"Petra","family":"Dibbets-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4892-3109","authenticated-orcid":false,"given":"Martin","family":"Pool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-6766","authenticated-orcid":false,"given":"Dennis","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"12","key":"7662_CR1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856\u201383.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"7662_CR2","doi-asserted-by":"publisher","first-page":"e000359","DOI":"10.1136\/esmoopen-2018-000359","volume":"3","author":"M Tahara","year":"2018","unstructured":"Tahara M. Management of recurrent or metastatic thyroid cancer. ESMO Open. 2018;3(Suppl 1):e000359.","journal-title":"ESMO Open"},{"key":"7662_CR3","doi-asserted-by":"crossref","unstructured":"Pacini F et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J, 2022. 11(1).","DOI":"10.1530\/ETJ-21-0046"},{"key":"7662_CR4","doi-asserted-by":"crossref","unstructured":"Narayanan S, Colevas A. Current standards in treatment of radioiodine refractory thyroid cancer. Curr Treat Options Oncol, 2016. 17(30).","DOI":"10.1007\/s11864-016-0404-6"},{"issue":"6","key":"7662_CR5","doi-asserted-by":"publisher","first-page":"R301","DOI":"10.1530\/ERC-15-0300","volume":"22","author":"F Vaisman","year":"2015","unstructured":"Vaisman F, Carvalho D, Vaisman M. A new appraisal of iodine refractory thyroid cancer. Endocrine-related Cancer. 2015;22(6):R301\u2013310.","journal-title":"Endocrine-related Cancer"},{"key":"7662_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"Fugazzola L, et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8:227\u201345.","journal-title":"Eur Thyroid J"},{"issue":"8","key":"7662_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"7662_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti S, et al. Esmo clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674\u201384.","journal-title":"Ann Oncol"},{"issue":"7","key":"7662_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330.","journal-title":"N Engl J Med"},{"issue":"9940","key":"7662_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"M Brose","year":"2014","unstructured":"Brose M, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet"},{"issue":"11","key":"7662_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1089\/thy.2019.0143","volume":"29","author":"A Iravani","year":"2019","unstructured":"Iravani A, et al. Mitogen-activated protein kinase pathway Inhibition for redifferentiation of radioiodine refractory differentiated thryoid cancer: an evolving protocol. Thyroid Cancer Nodules. 2019;29(11):1634\u201345.","journal-title":"Thyroid Cancer Nodules"},{"issue":"10","key":"7662_CR12","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1210\/jc.2018-00612","volume":"103","author":"T Jaber","year":"2018","unstructured":"Jaber T, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive radioiodine. J Clin Endocrinol Metabolism. 2018;103(10):3698\u2013705.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"7662_CR13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"L Dunn","year":"2019","unstructured":"Dunn L, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancer. J Clin Endocrinol Metabolism. 2019;104(5):1417\u201328.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"7","key":"7662_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"A Ho","year":"2013","unstructured":"Ho A, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623\u201332.","journal-title":"N Engl J Med"},{"issue":"19","key":"7662_CR15","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"M Weber","year":"2022","unstructured":"Weber M, et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study. Clin Cancer Res. 2022;28(19):4194\u2013202.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7662_CR16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","volume":"21","author":"S Rothenberg","year":"2014","unstructured":"Rothenberg S, et al. Redifferentation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with Dabrafenib. Clin Cancer Res. 2014;21(5):1028\u201335.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"7662_CR17","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux S, et al. A phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res. 2023;29(13):2401\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7662_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2021.0565","volume":"32","author":"V Tchekmedyian","year":"2022","unstructured":"Tchekmedyian V, et al. Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with Vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid. 2022;32(3):273\u201382.","journal-title":"Thyroid"},{"key":"7662_CR19","doi-asserted-by":"crossref","unstructured":"van Houten P et al. Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma. Eur Thyroid J, 2024. 13(4).","DOI":"10.1530\/ETJ-24-0153"},{"issue":"9","key":"7662_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11091382","volume":"11","author":"M Aashiq","year":"2019","unstructured":"Aashiq M, et al. Radioiodine-refractory thryoid cancer: molecular basis of redifferentation therapies, management and novel therapies. Cancers (Basel). 2019;11(9):1\u201315.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"7662_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","volume":"34","author":"J Liu","year":"2019","unstructured":"Liu J, et al. Radioactive iodine-refractory differentiated thryoid cancer and redifferentiation therapy. Endocrinol Metabolism. 2019;34(3):215\u201325.","journal-title":"Endocrinol Metabolism"},{"key":"7662_CR22","doi-asserted-by":"crossref","unstructured":"Dotinga M et al. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory thyroid cancer using lenvatinib (RESET): study protocol for a Single-Center. Open Label Phase II Trial Diagnostics (Basel), 2022. 12(12).","DOI":"10.3390\/diagnostics12123154"},{"issue":"1","key":"7662_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818789361","volume":"25","author":"K Suyama","year":"2018","unstructured":"Suyama K, Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361.","journal-title":"Cancer Control"},{"issue":"2","key":"7662_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.21873\/invivo.12313","volume":"35","author":"A Anschlag","year":"2021","unstructured":"Anschlag A, et al. Effect of kinase inhibitors on the Technetium-99m uptake into thyroid carcinoma cells in vitro. In Vivo. 2021;35(2):721\u20139.","journal-title":"In Vivo"},{"issue":"6","key":"7662_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1530\/EJE-09-0702","volume":"161","author":"H Hoftijzer","year":"2009","unstructured":"Hoftijzer H, et al. Beneficial effects of Sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923\u201331.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"7662_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"R Tuttle","year":"2019","unstructured":"Tuttle R, et al. Controversies, consensus, and collaboration in the use of I-131 therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association. Thyroid. 2019;29(4):461\u201370.","journal-title":"Thyroid"},{"issue":"6","key":"7662_CR27","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2967\/jnumed.114.153031","volume":"56","author":"W Jentzen","year":"2015","unstructured":"Jentzen W, Bockisch A, Ruhlmann M. Assessment of simplified blood dose protocols for the Estimation of the maximum tolerable activity in thyroid cancer patients undergoing radioiodine therapy using I-124. J Nucl Med. 2015;56(6):832\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"7662_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.107.047159","volume":"49","author":"W Jentzen","year":"2008","unstructured":"Jentzen W, et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49(6):1017\u201323.","journal-title":"J Nucl Med"},{"key":"7662_CR29","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","volume":"35","author":"M Lassmann","year":"2008","unstructured":"Lassmann M, et al. EANM dosimetry committe series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thryoid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7662_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"O JH","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"2","key":"7662_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7662_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2025.104935","volume":"131","author":"A van de Burgt","year":"2025","unstructured":"van de Burgt A. [18F]FDG administered activity reduction capabilities of a 32-cm axial field-of-view solid-state digital bismuth germanium oxide PET\/CT system while maintaining EARL compliance. Phys Med. 2025;131:104935.","journal-title":"Phys Med"},{"key":"7662_CR33","unstructured":"Dotinga M et al. A Phantom study to achieve comparable 124I PET recovery and address scanner variability for dosimetry purposes in (re)differentiated thyroid cancer. Phys Med. Under peer review."},{"issue":"1","key":"7662_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, et al. IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88.","journal-title":"EJNMMI Res"},{"issue":"11","key":"7662_CR35","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1172\/JCI89067","volume":"126","author":"J Nagarajah","year":"2016","unstructured":"Nagarajah J, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest. 2016;126(11):4119\u201324.","journal-title":"J Clin Invest"},{"issue":"10","key":"7662_CR36","first-page":"1603","volume":"31","author":"L Groussin","year":"2021","unstructured":"Groussin L, et al. Letter to the editor: Selpercatinib-Enhanced radioiodine uptake in RET-Rearranged thyroid cancer. Thyroid\u00ae. 2021;31(10):1603\u20134.","journal-title":"Thyroid\u00ae"},{"issue":"17","key":"7662_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1056\/NEJMc2023094","volume":"383","author":"L Groussin","year":"2020","unstructured":"Groussin L, Clerc J, Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. N Engl J Med. 2020;383(17):1686\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"7662_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1089\/thy.2021.0524","volume":"32","author":"L Groussin","year":"2022","unstructured":"Groussin L, et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid. 2022;32(5):594\u20138.","journal-title":"Thyroid"},{"key":"7662_CR39","doi-asserted-by":"crossref","unstructured":"Lee YA et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest, 2021. 131(18).","DOI":"10.1172\/JCI144847"},{"issue":"3","key":"7662_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13402-021-00588-y","volume":"44","author":"T Crezee","year":"2021","unstructured":"Crezee T, et al. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer. Cell Oncol (Dordr). 2021;44(3):611\u201325.","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"7662_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-024-06991-5","volume":"52","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2025","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, et al. Radioiodine-refractory thyroid cancer-is it time to change the definition in light of novel redifferentiation therapies? Eur J Nucl Med Mol Imaging. 2025;52(2):380\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7662_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2016.0246","volume":"26","author":"CL Jillard","year":"2016","unstructured":"Jillard CL, et al. Radioactive iodine treatment is associated with improved survival for patients with H\u00fcrthle cell carcinoma. Thyroid. 2016;26(7):959\u201364.","journal-title":"Thyroid"},{"issue":"3","key":"7662_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2967\/jnumed.111.096016","volume":"53","author":"D Van Nostrand","year":"2012","unstructured":"Van Nostrand D, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med. 2012;53(3):359\u201362.","journal-title":"J Nucl Med"},{"issue":"7","key":"7662_CR44","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2967\/jnumed.116.179366","volume":"58","author":"D Plyku","year":"2017","unstructured":"Plyku D, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in (124)I PET\/CT-based dosimetry for (131)I therapy of metastatic differentiated thyroid cancer. J Nucl Med. 2017;58(7):1146\u201354.","journal-title":"J Nucl Med"},{"issue":"4","key":"7662_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02626.x","volume":"65","author":"C P\u00f6tzi","year":"2006","unstructured":"P\u00f6tzi C, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf). 2006;65(4):519\u201323.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7662_CR46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.23736\/S1824-4785.20.03264-1","volume":"64","author":"M Dotinga","year":"2020","unstructured":"Dotinga M, et al. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. Q J Nucl Med Mol Imaging. 2020;64:250\u201364.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"7662_CR47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster M, et al. European association of nuclear medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7662_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.16956\/jes.2024.24.3.49","volume":"24","author":"SY Kim","year":"2024","unstructured":"Kim SY. Clinical considerations of oncocytic thyroid cancer: a review. J Endocr Surg. 2024;24(3):49\u201355.","journal-title":"J Endocr Surg"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07662-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:01:43Z","timestamp":1777276903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7662"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07662-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Medical Ethics Committee Leiden-Den Haag-Delft (ref. no. P20.096). The study was conducted according to the principles of the Declaration of Helsinki (10th version, Fortaleza 2013) and in concordance with the Dutch Medical Research Involving Human Subjects Act and other applicable guidelines, regulations, and acts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NIH ClinicalTrials.gov, NTC04858867, registered 26 April 2021.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"PD and FV have received speaker honoraria from GE HealthCare (fees received by institution). EK has consultancy\/advisory relationships with Delcath, Immunocore and BMS, and received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre-Fabre (fees received by institution).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}